Literature DB >> 8814744

Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study.

H B Hoh1, C Hurley, C Claoue, M Viswalingham, D L Easty, P Goldschmidt, L M Collum.   

Abstract

AIMS: This study was designed to assess the relative efficacy of topical ganciclovir 0.15% gel and acyclovir 3% ointment in the treatment of herpes simplex dendritic keratitis.
METHODS: Both treatment modalities were administered on a five times daily basis to patients suffering from herpes simplex keratitis. Patients were assigned randomly to one of the two treatment groups for the purpose of the trial. They were then examined on days 2, 7, 10, and 14 to assess the rate of healing of the dendritic ulceration.
RESULTS: There was no statistically significant difference detected in the rate of healing between the two treatment groups over the course of the trial.
CONCLUSIONS: Review of the relative efficacy of topical ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis showed that both treatment modalities were equally effective in their ability to heal the viral induced corneal ulceration. There were no significant side effects or adverse effects reported for either treatment modality.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814744      PMCID: PMC505405          DOI: 10.1136/bjo.80.2.140

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  31 in total

1.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Anti-herpes simplex virus (HSV) effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea.

Authors:  H Shiota; T Naito; Y Mimura
Journal:  Curr Eye Res       Date:  1987-01       Impact factor: 2.424

3.  Ganciclovir for chronic active Epstein-Barr virus infection.

Authors:  Y Ishida; Y Yokota; H Tauchi; M Fukuda; T Takaoka; M Hayashi; H Matsuda
Journal:  Lancet       Date:  1993-02-27       Impact factor: 79.321

Review 4.  Antiviral activity and mechanism of action of ganciclovir.

Authors:  T Matthews; R Boehme
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification.

Authors:  G Q Yao; S Grill; W Egan; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  Randomised double-blind trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex amoeboid corneal ulceration.

Authors:  L M Collum; P Logan; D McAuliffe-Curtin; S O Hung; A Patterson; P J Rees
Journal:  Br J Ophthalmol       Date:  1985-11       Impact factor: 4.638

7.  The current management of herpetic eye disease.

Authors:  L M Collum; W J Power; A Collum
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

8.  Bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration: a double blind controlled study.

Authors:  W J Power; A Benedict-Smith; M Hillery; K Brady; L M Collum
Journal:  Curr Eye Res       Date:  1991       Impact factor: 2.424

9.  Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2'-fluoropyrimidine nucleosides.

Authors:  D F Smee; N L Campbell; T R Matthews
Journal:  Antiviral Res       Date:  1985-10       Impact factor: 5.970

Review 10.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

View more
  20 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

Review 2.  Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers).

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

3.  Alkoxylalkyl Esters of Nucleotide Analogs Inhibit Polyomavirus DNA Replication and Large T Antigen Activities.

Authors:  Nichodemus O Onwubiko; Suraya A Diaz; Marcela Krečmerová; Heinz Peter Nasheuer
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 4.  Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Authors:  Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

5.  The treatment of herpes simplex virus epithelial keratitis.

Authors:  K R Wilhelmus
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 6.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

7.  Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes.

Authors:  Joseph Colin
Journal:  Clin Ophthalmol       Date:  2007-12

8.  Topical ganciclovir in the treatment of acute herpetic keratitis.

Authors:  Khalid F Tabbara; Noorjehan Al Balushi
Journal:  Clin Ophthalmol       Date:  2010-08-19

Review 9.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

10.  Clinical aspects and prognosis of polymicrobial keratitis caused by different microbial combinations: a retrospective comparative case study.

Authors:  Ibrahim Inan Harbiyeli; Oguzhan Oruz; Elif Erdem; Burcu Cam; Mehtap Demirkazik; Arbil Acikalin; Filiz Kibar; Macit Ilkit; Fugen Yarkin; Meltem Yagmur
Journal:  Int Ophthalmol       Date:  2021-07-18       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.